Previous 10 | Next 10 |
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
PARSIPPANY, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the publication of its multinational Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-injection interscalene ...
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
PARSIPPANY, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will participate in an analyst-led fireside chat at the Jefferies 2019 Healthcare Conference at 10:00 AM ET on Tuesday, June 4, 2019. Live audio of the event can be accessed...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
PARSIPPANY, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the following two healthcare conferences: Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas, on Tuesday, May 14 at 3:00 PM PT (6:00 ...
– TAP block with EXPAREL provides significant reductions in opioids and pain scores – – Results presented at Society of Obstetric Anesthesia and Perinatology annual meeting – PARSIPPANY, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...
Pacira Biosciences, Inc. (PCRX) Q1 2019 Earnings Conference Call May 02, 2019, 08:30 ET Company Participants Susan Mesco - Head, IR David Stack - Chairman & CEO Richard Scranton - Chief Medical Officer Charles Reinhart - CFO Conference Call Participants David Amsellem...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...